Vanguard Group
GLUE icon

Vanguard Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Vanguard Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$50.9M Buy
3,246,500
+257,547
+9% +$3.47M ﹤0.01% 2153
2025
Q3 		$22.1M Sell
2,988,953
-151,557
-5% -$803K ﹤0.01% 2572
2025
Q2 		$14.2M Buy
3,140,510
+40,474
+1% +$181K ﹤0.01% 2723
2025
Q1 		$14.4M Sell
3,100,036
-56,318
-2% -$345K ﹤0.01% 2653
2024
Q4 		$21.9M Buy
3,156,354
+622,134
+25% +$4.67M ﹤0.01% 2542
2024
Q3 		$13.4M Sell
2,534,220
-12,855
-0.5% -$64.9K ﹤0.01% 2807
2024
Q2 		$9.53M Buy
2,547,075
+911,246
+56% +$4.65M ﹤0.01% 2958
2024
Q1 		$11.5M Buy
1,635,829
+47,412
+3% +$281K ﹤0.01% 2871
2023
Q4 		$8.97M Sell
1,588,417
-39,960
-2% -$157K ﹤0.01% 3010
2023
Q3 		$7.8M Buy
1,628,377
+71,589
+5% +$461K ﹤0.01% 3031
2023
Q2 		$10.7M Buy
1,556,788
+109,354
+8% +$707K ﹤0.01% 2912
2023
Q1 		$11.3M Buy
1,447,434
+20,720
+1% +$144K ﹤0.01% 2873
2022
Q4 		$10.9M Buy
1,426,714
+19,047
+1% +$159K ﹤0.01% 2919
2022
Q3 		$11.5M Sell
1,407,667
-855,239
-38% -$7.86M ﹤0.01% 2883
2022
Q2 		$21.9M Sell
2,262,906
-739,866
-25% -$7.43M ﹤0.01% 2594
2022
Q1 		$42.1M Buy
3,002,772
+1,922,156
+178% +$26.7M ﹤0.01% 2391
2021
Q4 		$22.1M Buy
1,080,616
+60,595
+6% +$1.27M ﹤0.01% 2783
2021
Q3 		$22.7M Buy
1,020,021
+920,021
+920% +$26.4M ﹤0.01% 2796
2021
Q2 		$2.27M Buy
+100,000
New +$2.04M ﹤0.01% 3936

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group's GLUE Position: Q4 2025 in Review

Vanguard Group increased its Monte Rosa Therapeutics (GLUE) stake by 8.6% in Q4 2025, buying an estimated $3.47M and bringing the position to 3,246,500 shares worth $50.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2153.

Vanguard Group first reported a position in GLUE in Q2 2021 and has held it in 19 quarters since. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Vanguard Group held 3,246,500 shares of Monte Rosa Therapeutics worth $50.9M as of Q4 2025.
  • Vanguard Group bought 257,547 Monte Rosa Therapeutics shares in Q4 2025, an estimated $3.47M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2153 holding.
  • Vanguard Group first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.